NasdaqGS - Delayed Quote USD

Zynex, Inc. (ZYXI)

10.88 -0.12 (-1.09%)
At close: May 17 at 4:00 PM EDT
10.84 -0.04 (-0.37%)
After hours: May 17 at 4:06 PM EDT
Loading Chart for ZYXI
DELL
  • Previous Close 11.00
  • Open 11.01
  • Bid 10.84 x 100
  • Ask 10.94 x 100
  • Day's Range 10.84 - 11.01
  • 52 Week Range 6.88 - 13.77
  • Volume 61,968
  • Avg. Volume 165,806
  • Market Cap (intraday) 345.714M
  • Beta (5Y Monthly) 0.49
  • PE Ratio (TTM) 47.30
  • EPS (TTM) 0.23
  • Earnings Date Jul 25, 2024 - Jul 29, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date Jan 5, 2022
  • 1y Target Est 19.88

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain; and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body, and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, and braces for rehabilitation support. Further, it offers Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser-based noninvasive co-oximeter; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; hemodynamic monitoring and intravascular volume monitoring; and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado.

www.zynex.com

1,100

Full Time Employees

December 31

Fiscal Year Ends

Recent News: ZYXI

Performance Overview: ZYXI

Trailing total returns as of 5/17/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

ZYXI
0.09%
S&P 500
11.18%

1-Year Return

ZYXI
14.89%
S&P 500
29.04%

3-Year Return

ZYXI
12.76%
S&P 500
27.06%

5-Year Return

ZYXI
60.91%
S&P 500
84.38%

Compare To: ZYXI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: ZYXI

Valuation Measures

Annual
As of 5/17/2024
  • Market Cap

    345.71M

  • Enterprise Value

    388.29M

  • Trailing P/E

    47.24

  • Forward P/E

    21.74

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    2.02

  • Price/Book (mrq)

    10.44

  • Enterprise Value/Revenue

    2.06

  • Enterprise Value/EBITDA

    22.86

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    4.33%

  • Return on Assets (ttm)

    5.81%

  • Return on Equity (ttm)

    16.75%

  • Revenue (ttm)

    188.68M

  • Net Income Avi to Common (ttm)

    8.17M

  • Diluted EPS (ttm)

    0.23

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    32.86M

  • Total Debt/Equity (mrq)

    227.90%

  • Levered Free Cash Flow (ttm)

    19.45M

Research Analysis: ZYXI

Company Insights: ZYXI

Research Reports: ZYXI

People Also Watch